LACK OF AN EFFECT OF MADOPAR ON THE DISPOSITION OF TOLCAPONE AND ITS 3-O-METHYLATED METABOLITE IN RATS

被引：5

作者：

FUNAKI, T ^{[1
]}

ONODERA, H ^{[1
]}

USHIYAMA, N ^{[1
]}

TSUKAMOTO, Y ^{[1
]}

TAGAMI, C ^{[1
]}

FUKAZAWA, H ^{[1
]}

KURUMA, I ^{[1
]}

机构：

[1] NIPPON ROCHE RES CTR,KAMAKURA,KANAGAWA 247,JAPAN

来源：

JOURNAL OF PHARMACY AND PHARMACOLOGY | 1995年 / 47卷 / 06期

关键词：

D O I：

10.1111/j.2042-7158.1995.tb05846.x

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The effect of Madopar (benserazide and L-dopa, 1:4) on the disposition of the new selective inhibitor of catechol-O-methyltransferase, tolcapone, in rats was investigated. There was no statistically significant difference in the pharmacokinetic parameters of tolcapone in the presence or absence of Madopar except for a change in the mean residence time after oral administration. Thus, we rejected the hypothesis that the consumption of S-adenyl-L-methionine by Madopar would change the disposition of tolcapone. There were no statistically significant differences in the cumulative amount absorbed of drug and the absorption rate in the presence or absence of Madopar. We concluded that there was no interaction between tolcapone and Madopar.

引用

页码：539 / 542

页数：4

共 11 条

[1]

Funaki T., Onodera H., Ushiyama N., Tsukamoto Y., Tagami C., Fukazawa H., Kuruma I., The disposition of the tolcapone 3‐O‐methylated metabolite is affected by the route of administration in rats, J. Pharm. Pharmacol., 46, pp. 571-574, (1994)

[2]

Iga K., Ogawa Y., Yashiki T., Shimamoto T., Estimation of drug absorption rates using a deconvolution method with nonequal sampling time, J. Pharmacokinet. Biopharm., 14, pp. 213-225, (1986)

[3]

Jeffery D.R., Roth J.A., Purification and kinetic mechanism of human brain soluble catechol‐O‐methyltransferase, J. Neurochem., 44, pp. 881-885, (1985)

[4]

Kaakkola S., Gordin A., Jarvinen M., Wikberg T., Schultz E., Nissinen E., Pentikainen P.J., Rita H., Effect of a novel catechol‐O‐methyltransferase inhibitor, nitecapone, on the metabolism of l‐dopa in healthy volunteers, Clin. Neuropharmacol., 13, pp. 436-447, (1990)

[5]

Lennernas H., Nilsson D., Aquilonius S., Ahrenstedt O., Knutson L., Paalzow L.K., The effect of l‐leucine on the absorption of levodopa, studied by regional jejunal perfusion in man, Br. J. Clin. Pharmacol., 35, pp. 243-250, (1993)

[6]

Nissinen E., Tuominen R., Perhoniemi V., Kaakkola S., Catechol‐O‐methyltransferase activity in human and rat small intestine, Life Sci., 42, pp. 2609-2614, (1988)

[7]

Rabey J.M., Oberman Z., Scharf M., Isakov A., Bar M., Graff E., The influence of levodopa in the pharmacokinetics of bromocriptine in Parkinson's disease, Clin. Neuropharmacol., 12, pp. 440-447, (1989)

[8]

Rose S., Jenner P., Marsden C.D., Peripheral pharmacokinetic handling and metabolism of l‐dopa in the rat: the effect of route of administration and carbidopa pretreatment, J. Pharm. Pharmacol., 43, pp. 325-330, (1991)

[9]

Veng-Pedersen P., Gillespie W.R., A method for evaluating the mean residence time of metabolites in the body, systemic circulation, and the peripheral tissue not requiring separate i.v. administration of metabolite, Biopharmaceutics & Drug Disposition, 8, pp. 395-401, (1987)

[10]

Yamaoka K., Tanigawara Y., Nakagawa T., Uno T., A pharmacokinetic analysis program (MULTI) for microcomputer, J. Pharmacobiodyn., 4, pp. 879-885, (1981)

← 1 2 →